Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers
- Registration Number
- NCT02276365
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The objective of the study was to investigate whether there is a drug-drug interaction between BI 10773 and pioglitazone when co-administered as multiple oral doses. Therefore, the relative bioavailabilities of BI 10773 and pioglitazone were determined when both drugs were given in combination compared with BI 10773 and pioglitazone given alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
-
Healthy males according to the following criteria:
- Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead ECG (electrocardiogram), clinical laboratory tests
-
Age 18 to 50 years (incl.)
-
BMI 18.5 to 29.9 kg/m2 (incl.)
-
Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation
Exclusion Criteria
- Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of the gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- Intake of drugs with a long half-life (more than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (more than 10 cigarettes or more than 3 cigars or more than 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (more than 30 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- ALT (Alanine transaminase) outside the normal range or any other laboratory value outside the reference range that is of clinical relevance
- Inability to comply with dietary regimen of trial site
- Galactose or lactose intolerance, galactose or glucose malabsorption
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Sequence ABC Pioglitazone 1. Treatment A: 50 mg BI 10773 once daily from day 1 to 5 2. Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7 3. Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out Sequence CAB BI 10773 1. Treatment C: 45 mg pioglitazone once daily from day 1 to 7 2. Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out 3. Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7 Sequence ABC BI 10773 1. Treatment A: 50 mg BI 10773 once daily from day 1 to 5 2. Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7 3. Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out Sequence CAB Pioglitazone 1. Treatment C: 45 mg pioglitazone once daily from day 1 to 7 2. Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out 3. Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7
- Primary Outcome Measures
Name Time Method Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) up to 10 days AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) up to 10 days
- Secondary Outcome Measures
Name Time Method tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ) up to 10 days t½,ss (terminal half-life of the analyte in plasma at steady state) up to 10 days Changes from baseline in vital signs (Blood pressure, pulse rate) Baseline and up to 10 days after last study drug administration Changes from baseline in 12-lead ECG (electrocardiogram) Baseline and up to 10 days after last study drug administration C24,N (concentration of analyte in plasma at 24 hours post-drug administration after administration of the Nth dose) up to 10 days λz,ss (terminal half-life of the analyte in plasma) up to 10 days CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state) up to 10 days Changes in clinical laboratory tests Baseline and up to 10 days after last study drug administration Incidence of adverse events up to 35 days MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration) up to 10 days CLR,ss (renal clearance of the analyte at steady state) 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing Assessment of tolerability by investigator on a 4-point scale Within 3-10 days after last study drug administration UGE0-24 (Urinary glucose excretion of the analyte in urine over the time interval from time zero to 24 h) 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing Aet1-t2,ss (amount of analyte eliminated in urine at steady state over a uniform dosing interval τ) 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing fet1-t2,ss (fraction of analyte excreted unchanged in urine at steady state over a uniform dosing interval τ) 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing Abnormal findings in physical examination Baseline and up to 10 days after last study drug administration Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration) up to 10 days